



Published in final edited form as:

*Mov Disord.* 2020 July ; 35(7): 1253–1257. doi:10.1002/mds.28038.

## Progressive Supranuclear Palsy and Statin Use

Ece Bayram, MD, PhD<sup>1</sup>, Connie Marras, MD, PhD<sup>2</sup>, David G. Standaert, MD, PhD<sup>3</sup>, Benzi M. Kluger, MD<sup>4</sup>, Yvette M. Bordelon, MD, PhD<sup>5</sup>, David R. Shprecher, DO, MSci<sup>6,7</sup>, Irene Litvan, MD<sup>1,\*</sup>, the ENGENE-PSP Consortium

<sup>1</sup>Movement Disorders Center, Department of Neurosciences, University of California San Diego, San Diego, CA, USA

<sup>2</sup>Morto and Gloria Shulman Movement Disorders Centre and The Edmond J Safra Program in Parkinson's Research, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada

<sup>3</sup>Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA

<sup>4</sup>Department of Neurology, University of Colorado, Aurora, Colorado, USA

<sup>5</sup>Department of Neurology, University of California Los Angeles, California, USA

<sup>6</sup>Department of Neurology, University of Utah, Salt City, Utah, USA

<sup>7</sup>Department of Neurology, University of Arizona, Phoenix, Arizona, USA

### Abstract

**Introduction:** Statins were proposed to be neuroprotective; however, the effects are unknown in progressive supranuclear palsy (PSP), a pure tauopathy.

**Methods:** Data of 284 PSP cases and 284 age-matched, sex-matched, and race-matched controls were obtained from the environmental and genetic PSP (ENGENE-PSP) study. Cases were evaluated with the PSP Rating Scale, Unified Parkinson's Disease Rating Scale, Mattis Dementia Rating Scale, and Neuropsychiatric Inventory. Statin associations with PSP risk, onset age, and disease features were analyzed.

**Results:** Univariate models showed lower PSP risk for type 1 statin users (simvastatin, lovastatin, pravastatin). After adjusting for confounding variables, statin use and lower PSP risk association remained only at a trend level. For PSP cases, type 1 statins were associated with 1-year older onset age; type 2 statins (atorvastatin, rosuvastatin) were associated with the lower PSP Rating Scale and Unified Parkinson's Disease Rating Scale.

**Conclusion:** Statins may have inverse associations with PSP risk and motor impairment. Randomized prospective studies are required to confirm this effect.

\* **Correspondence to:** Dr. Irene Litvan, University of California San Diego Department of Neurosciences, Movement Disorders Center, Altman Clinical Translational Research Institute, 9452 Medical Center Dr, 2W-114, La Jolla, CA 92037; [ilitvan@ucsd.edu](mailto:ilitvan@ucsd.edu).

**Relevant conflicts of interests/financial disclosures:** All authors, except for Dr. Bayram, were members of the ENGENE-PSP Consortium and received funding from National Institute on Aging 5R01AG024040 for their contribution to the study.

Supporting Data

Additional Supporting Information may be found in the online version of this article at the publisher's web-site.

## Keywords

case-control; progressive supranuclear palsy; statins; tauopathy

Progressive supranuclear palsy (PSP) is a tauopathy presenting with postural instability, parkinsonism, ocular motor dysfunction, and executive dysfunction,<sup>1</sup> without any disease-modifying agents or effective treatment options.<sup>2</sup> Statins, primarily used for ischemic heart disease management and prevention, are one of the most commonly used drugs worldwide. In addition to reducing plasma cholesterol levels, statins may be neuroprotective through antioxidant, anti-inflammatory, and immunomodulatory mechanisms.<sup>3</sup> In a tauopathy animal model, using statins before neurofibrillary tangle development significantly decreased the tangle burden under both normocholesterolemic and hypercholesterolemic conditions.<sup>4</sup> However, statin effects on tauopathies in a clinical sample have not been investigated, apart from Alzheimer's disease (AD). As AD is a mixture of pathologies including 3R tauopathy, 4R tauopathy, and  $\beta$ -amyloid deposition,<sup>5</sup> the results cannot be generalized to PSP, a primary 4R tauopathy. Therefore, we aimed to determine whether statins are inversely associated with PSP development and symptoms using an age-matched, sex-matched, and race-matched case-control sample.

## Methods

Data were obtained from the environmental and genetic PSP (ENGINE-PSP) study, previously described elsewhere.<sup>6</sup> The inclusion criteria for the cases were the following: (1) PSP diagnosis within the past year by the principal investigator at the screening site (based on the National Institute for Neurological Disorders and Society for PSP criteria for probable PSP<sup>7</sup>), (2) no other central nervous system pathology, and (3) Mini-Mental Status Examination score of  $>24$  to exclude cognitive impairment. Controls, screening negative for parkinsonism and dementia, consisted of non-blood relatives or friends of the included PSP patients. A total of 350 incident PSP patients and 300 healthy controls meeting the inclusion criteria were recruited in 15 sites in North America between October 2006 and February 2013. Of the cases, 66 did not have a matched control and were excluded (50 without matched controls, 16 without race-matched controls), leading to 284 cases and 284 age-matched, sex-matched, and race-matched controls included in our analysis. The institutional review boards of each site approved the ENGINE-PSP, and the participants provided written informed consent prior to participation.

A list of all medications taken for more than 6 months since the age of 30, the reason of use, and the years of first and last use were collected during an in-person visit. Statin use was defined as having used statins before the onset of symptoms for cases and before the visit for controls. All PSP patients underwent clinical evaluations with standardized measures including PSP Rating Scale (PSPRS), Unified Parkinson's Disease Rating Scale (UPDRS), Mattis Dementia Rating Scale (DRS), and Neuropsychiatric Inventory (NPI).

Statistics were done with IBM (Armonk, NY) SPSS version 26.0. Demographics and statin data were compared between cases and controls with chi-square and *t* tests with Bonferroni correction for multiple comparisons. The association between statin use and PSP diagnosis

was evaluated by conditional logistic regression, with case/control pairs as stratum and case status as the outcome. First, univariate models were performed to identify the possible confounders, then a multivariate model was performed including confounding variables with a  $P < 0.05$  from the first model. The associations between statin use and age at symptom onset, PSPRS, UPDRS, DRS, and NPI were assessed by stepwise linear regression, adjusting for potential confounders from univariate models as explained previously. The effects of different statins were analyzed by grouping the statins based on their chemical structures<sup>8</sup> (type 1 statins: simvastatin, lovastatin, pravastatin; type 2 statins: atorvastatin, rosuvastatin) because of the low number of participants having used individual statins.  $P < 0.05$  was considered statistically significant.

## Results

Demographics and clinical features are summarized in Table 1. Compared with the controls, cases had lower years of education, higher years of drinking well water and smoking, pack-years, and were less likely to have used statins. Type 2 statin use, age at first statin use, and duration of statin use were not different between cases and controls. Compared with the controls, a lower ratio of cases had used type 1 statins. Of the participants, 8.4% of the cases and 5.8% of the controls had a history of more than 1 type of statin use. More smoking pack-years and years of drinking well water were associated with increased PSP risk. More years of education and statin use—type 1 in particular (not type 2)—were associated with lower PSP risk based on univariate models (Table 1).

Multivariate model results for statin and disease parameters are shown in Table 2 (univariate model results are given in Supplementary Table 1). After adjusting for confounding variables, statin use and lower PSP risk association remained only at a trend-level ( $P = 0.05$ ). Statin use was associated with 1-year older age at symptom onset, approximately 4-point lower PSPRS and UPDRS-Part III scores, and 7-point lower UPDRS-Total scores without any association with DRS or NPI. For controls, the association between age and statin use did not reach a significant level (B [95% confidence interval] = 1.83 [−0.049 to 3.71],  $P = 0.056$ ).

After adjusting for confounding variables, type 1 statins were not associated with PSP risk. Type 1 statins were associated with 1-year older symptom onset age, without any associations with disease parameters. Type 2 statins were associated with approximately 5-point lower PSPRS and UPDRS-Part III scores and 7-point lower UPDRS-Total scores without any associations with symptom onset age, DRS, or NPI. Age at first statin use or duration of statin use were not associated with PSP risk or disease features.

## Discussion

In this study, the associations between statins and PSP risk, age at symptom onset, and disease features were evaluated. Statin use was associated with lower PSP risk, although the significance remained at a trend-level once adjusted for confounding variables. For cases, statin use was significantly associated with an older symptom onset age. Although 1-year delay may not be clinically significant for some neurodegenerative disorders, it can be very



Our results showed that type 1 statins are associated with reduced risk and delayed onset, whereas type 2 statins were associated with less motor impairment. Previously, comparisons of multiple statin types suggested that simvastatin (a type 1 statin) might provide most efficacy for neuropathological conditions considering blood–brain barrier penetration, safety, cholesterol reduction in neurons, and neuroprotection in cell cultures.<sup>15</sup> Although our sample size of statin users did not allow us to assess each statin type individually, certain statins may be more or less effective in PSP. In addition, some participants had a history of more than 1 type of statin use, suggesting a cautious interpretation of our findings. We did not have detailed information on the dosage of statins to evaluate dose-dependent effects. Considering that the participants were on statins for hypercholesterolemia, the beneficial effects of statins in PSP may require different doses or specific types of statins given that blood–brain barrier permeabilities and effects on low-density and high-density lipoprotein cholesterol differ between statin types.<sup>15</sup>

To conclude, statins were associated with potentially lower PSP risk, delayed symptom onset, and less severe motor symptoms, with different effects found for type 1 and 2 statins. The potential statin effects require future investigations, as there is an urgent need for efficient therapeutic approaches in PSP.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments:

The authors hereby acknowledge all the persons who generously participated in the study. The following ENGENE-PSP Consortium Site Investigators recruited 9 patients or more, listed according to number of cases and controls recruited: Irene Litvan, MD, from the University of Louisville; Jorge Juncos, MD, from Emory University; David Riley, MD, from Case Western Reserve University; Yvette Bordelon, MD, PhD, from University of California Los Angeles; Stephen Reich, MD, from the University of Maryland; Deborah Hall, MD, PhD, from Rush University and University of Colorado; David Standaert, MD, PhD, from the University of Alabama in Birmingham; David Shprecher, DO, MSci, from the University of Utah; Connie Marras, MD, PhD, from the University of Toronto; Benzi Kluger, MD, from the University of Colorado and Joseph Jankovic, MD, from Baylor College of Medicine. The authors also thank the referral of fewer than 9 patients from the ENGENE Coinvestigators: Richard Dubinsky, MD, MPH, Kansas University; Claire Henchcliffe MD, PhD, Cornell University; Ryan Uitti, MD, Mayo Clinic Jacksonville and James Leverenz, MD, University of Washington. All members of the ENGENE-PSP study were funded by National Institute on Aging 5R01AG024040. The National Institute on Aging had no role in study design, data collection, data analysis, data interpretation, or writing this report.

**Funding agency:** Data used in this study was from the ENGENE-PSP Consortium funded by the National Institute on Aging 5R01AG024040.

## References

1. Höglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the Movement Disorder Society Criteria. *Mov Disord* 2017;32(6):853–864. [PubMed: 28467028]
2. Boxer AL, Yu JT, Golbe LI, Litvan I, Lang AE, Höglinger GU. Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. *Lancet Neurol* 2017;16(7): 552–563. [PubMed: 28653647]
3. Wang Q, Yan J, Chen X, et al. Statins: multiple neuroprotective mechanisms in neurodegenerative diseases. *Exp Neurol* 2011;230(1):27–34. [PubMed: 20406638]

4. Boimel M, Grigoriadis N, Loubopoulos A, et al. Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy. *J Neuropathol Exp Neurol* 2009;68(3):314–325. [PubMed: 19225406]
5. Irwin DJ. Tauopathies as clinicopathological entities. *Parkinsonism Relat Disord* 2016;22(suppl 1):S29–S33. [PubMed: 26382841]
6. Litvan I, Lees PSJ, Cunningham CR, et al. Environmental and occupational risk factors for progressive supranuclear palsy: case-control study. *Mov Disord* 2016;31(5):644–652. [PubMed: 26854325]
7. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. *Neurology* 1996;47(1):1–9. [PubMed: 8710059]
8. Hennessy E, Adams C, Reen FJ, O’Gara F. Is there potential for repurposing statins as novel antimicrobials? *Antimicrob Agents Chemother* 2016;60(9):5111–5121. [PubMed: 27324773]
9. Respondek G, Hoglinger GU. The phenotypic spectrum of progressive supranuclear palsy. *Park Relat Disord* 2016;22: S34–S36.
10. McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. *Cochrane Database Syst Rev* 2016;2016(1): CD003160.
11. Geifman N, Brinton RD, Kennedy RE, Schneider LS, Butte AJ. Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer’s disease. *Alzheimer’s Res Ther* 2017;9(1):10. [PubMed: 28212683]
12. Rabadia SV, Litvan I, Juncos J, et al. Hypertension and progressive supranuclear palsy. *Parkinsonism Relat Disord* 2019;66: 166–170. [PubMed: 31420308]
13. Fernández-Botrán R, Ahmed Z, Crespo FA, et al. Cytokine expression and microglial activation in progressive supranuclear palsy. *Park Relat Disord* 2011;17(9):683–688.
14. Pulli B, Chen J. Imaging neuroinflammation—from bench to bedside. *J Clin Cell Immunol* 2014;5:226. [PubMed: 25525560]
15. Sierra S, Ramos MC, Molina P, Esteo C, Vázquez JA, Burgos JS. Statins as neuroprotectants: a comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. *J Alzheimer’s Dis* 2011;23(2):307–318. [PubMed: 21098985]

TABLE 1.

Demographics and clinical features

Features	Cases, n = 284	Controls, n = 284	Cases vs. Controls, P Value	Odds Ratio (95% CI) for PSP Risk*
Age	68.8 (7.01)	69.0 (7.44)	1.00	-
Sex, female	50.4	50.4	1.00	-
Race			1.00	-
White or European American	97.5	97.5		
Black or African American	0.7	0.7		
Asian or Pacific Islander	1.8	1.8		
Income			0.067	-
<\$50,000/year	36.4	27.1		
\$50–80,000/year	27.1	28.6		
>\$80,000/year	36.4	44.3		
Years of education	14.7 (4.21)	16.2 (4.07)	<0.001	0.89 (0.84–0.93)
Smoking, pack-years	15.7 (25.1)	10.5 (19.5)	0.032	1.01 (1.01–1.02)
Years of drinking well water	11.4 (17.0)	7.10 (12.4)	0.003	1.02 (1.01–1.04)
Age at symptom onset	65.03 (7.01)	-		
PSP symptom duration, years	3.68 (1.76)	-		
PSP Rating Scale	36.3 (11.3)	-		
UPDRS-Total	51.7 (17.9)	-		
UPDRS-Part III	30.0 (12.3)	-		
Dementia Rating Scale	127 (10.8)	-		
Neuropsychiatric Inventory	10.1 (9.11)	-		
Statin use	20.8	30.6	0.011	0.61 (0.41–0.91)
Type 1 statins	10.9	17.6	0.023	0.56 (0.34–0.92)
Type 2 statins	11.6	14.8	0.27	-
Age at first statin use	59.2 (8.08)	62.1 (8.08)	0.19	-
Duration of statin use, years	7.48 (5.66)	6.24 (5.69)	0.97	-
Reason for statin use			0.80	-
Hypercholesterolemia	97.7	98.3		
Hypercholesterolemia & hypertension	2.3	1.7		

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Variables are reported as mean (standard deviation) or percentage. Bold indicates statistical significance.

\* Only significant variables from the univariate regression models are shown.

CI, confidence interval; PSP, progressive supranuclear palsy; UPDRS, Unified Parkinson's Disease Rating Scale.



TABLE 2.

Multivariate regression model results for associations between PSP features and statin use (model with 284 PSP cases), age at first statin use, and duration of statin use (model with 59 statin user PSP cases)

Statin parameters	PSP risk, odds ratio (95% CI) <sup>1</sup>	Age at symptom onset, <sup>2</sup> B (95% CI)	PSP Rating Scale, B (95% CI) <sup>3</sup>	UPDRS-Total, B (95% CI) <sup>4</sup>	UPDRS-Part III, B (95% CI) <sup>4</sup>	Dementia Rating Scale, <sup>5</sup> B (95% CI)	Neuropsychiatric Inventory, B (95% CI) <sup>4</sup>
Statin use	0.65 (0.43-1.00), P=0.050	1.00 (0.31-1.70), P=0.005	-3.80 (-7.03 to -0.56), P=0.022	-7.16 (-12.17 to -2.14), P=0.005	-4.48 (-7.89 to -1.06), P=0.010	1.43 (-1.64 to 4.50), P=0.36	0.55 (-2.42 to 3.53), P=0.71
Type 1 statin use	0.60 (0.35-1.03), P=0.064	1.09 (0.18-1.99), P=0.049	-1.47 (-5.69 to 2.76), P=0.50	-5.61 (-12.14 to 0.92), P=0.092	-3.10 (-7.55 to 1.35), P=0.17	-0.16 (-4.11 to 3.80), P=0.94	1.82 (-1.99 to 5.63), P=0.35
Type 2 statin use	0.81 (0.47-1.37), P=0.43	0.61 (0.003-0.03), P=0.17	-4.87 (-8.95 to -0.80), P=0.019	-6.83 (-13.18 to -0.48), P=0.035	-4.66 (-8.98 to -0.35), P=0.034	2.34 (-1.55 to 6.23), P=0.24	0.56 (-3.13 to 4.25), P=0.77
Age at first statin use	0.84 (0.67-1.05), P=0.12	0.06 (-0.003 to 0.13), P=0.061	0.03 (-0.31 to 0.36), P=0.88	-0.19 (-0.69 to 0.30), P=0.44	-0.11 (-0.54 to 0.32), P=0.61	-0.04 (-0.42 to 0.34), P=0.84	-0.03 (-0.49 to 0.43), P=0.90
Duration of statin use	1.04 (0.88-1.22), P=0.67	-0.02 (-0.10 to 0.06), P=0.59	0.13 (-0.35 to 0.60), P=0.59	0.61 (-0.08 to 1.30), P=0.083	0.36 (-0.12 to 0.85), P=0.14	-0.12 (-0.55 to 0.32), P=0.59	0.01 (-0.55 to 0.57), P=0.97

Bold indicates statistical significance. B values show the amount of increase in outcome measure with statin use (overall, types 1 and 2), and 1-year increase in age at first statin use or duration of statin use.

<sup>1</sup>Confounding variables in the model: years of education, smoking, pack-years, years of drinking well water.

<sup>2</sup>Confounding variables in the model: age, smoking, pack-years.

<sup>3</sup>Confounding variable in the model: ethnicity.

<sup>4</sup>Confounding variables in the model: age, years of education.

<sup>5</sup>Confounding variables in the model: age, sex, years of education, years of drinking well water.

PSP, progressive supranuclear palsy; CI, confidence interval; B, unstandardized beta coefficient; UPDRS, Unified Parkinson's Disease Rating Scale.